Scancell Hldgs Plc (LSE:SCLP) — Market Cap & Net Worth
Market Cap & Net Worth: Scancell Hldgs Plc (SCLP)
Scancell Hldgs Plc (LSE:SCLP) has a market capitalization of $1.22 Million (GBX10.07 Billion) as of September 24, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30565 globally and #779 in its home market, demonstrating a -2.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scancell Hldgs Plc's stock price GBX9.70 by its total outstanding shares 1037781403 (1.04 Billion). Also see Scancell Hldgs Plc total assets for a full breakdown of the balance sheet.
Scancell Hldgs Plc Market Cap History: 2015 to 2026
Scancell Hldgs Plc's market capitalization history from 2015 to 2026. Data shows change from $2.70 Million to $1.22 Million (-8.06% CAGR). Also see Scancell Hldgs Plc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Scancell Hldgs Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$1.02 Billion | 0.12% | #139 of 722 |
Weight: Scancell Hldgs Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Scancell Hldgs Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scancell Hldgs Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SCLP live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.27x
Scancell Hldgs Plc's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.33 Million | $5.27 Million | -$11.94 Million | 0.25x | N/A |
| 2025 | $1.25 Million | $4.71 Million | -$12.27 Million | 0.27x | N/A |
Competitor Companies of SCLP by Market Capitalization
Companies near Scancell Hldgs Plc in the global market cap rankings as of September 24, 2026. Review Scancell Hldgs Plc (SCLP) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Scancell Hldgs Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Scancell Hldgs Plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Scancell Hldgs Plc's market cap moved from $2.70 Million to $ 1.22 Million, with a yearly change of -8.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX1.22 Million | -2.02% |
| 2025 | GBX1.25 Million | -7.91% |
| 2024 | GBX1.36 Million | +2.38% |
| 2023 | GBX1.33 Million | -57.58% |
| 2022 | GBX3.13 Million | +23.75% |
| 2021 | GBX2.53 Million | +42.86% |
| 2020 | GBX1.77 Million | +97.25% |
| 2019 | GBX896.21K | -20.55% |
| 2018 | GBX1.13 Million | -28.22% |
| 2017 | GBX1.57 Million | -13.56% |
| 2016 | GBX1.82 Million | -32.74% |
| 2015 | GBX2.70 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Scancell Hldgs Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.22 Million USD |
| MoneyControl | $1.22 Million USD |
| MarketWatch | $1.22 Million USD |
| marketcap.company | $1.22 Million USD |
| Reuters | $1.22 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase I… Read more